|
How Much Should Medicare Pay For Drugs?
Joseph P. Newhouse
Discussions of the Medicare drug benefit have focused more on what beneficiaries will pay than what pharmaceutical manufacturers will receive. A key choice is the degree to which Medicare must become involved in setting manufacturers’ prices. If prices must be set, Medicare could do so using average wholesale price, comparison with prices in other markets, cost, or rate-of-return regulation. Because all four methods have substantial drawbacks, Medicare should not initially attempt to set prices, but to prevent abuses in pricing, Congress should allow cost to be considered in coverage decisions.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Levy, B. Harrigan, K. Johnston, and A. Briggs
Comparative Effectiveness Research Through the Looking Glass
Med Decis Making,
November 1, 2009;
29(6):
NP6 - NP8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. T. Schumock and A. S. Pickard
Comparative effectiveness research: Relevance and applications to pharmacy
Am. J. Health Syst. Pharm.,
July 15, 2009;
66(14):
1278 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fotaki, M. Roland, A. Boyd, R. McDonald, R. Scheaff, and L. Smith
What benefits will choice bring to patients? Literature review and assessment of implications
J Health Serv Res Policy,
July 1, 2008;
13(3):
178 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Frank and J. P. Newhouse
Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?
Health Aff.,
January 1, 2008;
27(1):
33 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Berry and N. Bendapudi
Health Care: A Fertile Field for Service Research
Journal of Service Research,
November 1, 2007;
10(2):
111 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Garcia-Altes, C. Borrell, L. Cote, A. Plaza, J. Benet, A. Guarga, and for the Montreal and Barcelona group on performanc
Measuring the performance of urban healthcare services: results of an international experience
J Epidemiol Community Health,
September 1, 2007;
61(9):
791 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kelley
Health, spending and the effort to improve quality in OECD countries: a review of the data
Perspectives in Public Health,
March 1, 2007;
127(2):
64 - 71.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. D. Ramsey
How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer Care in the United States
J. Clin. Oncol.,
January 10, 2007;
25(2):
175 - 179.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. kelley, I. Arispe, and J. Holmes
Beyond the initial indicators: lessons from the OECD Health Care Quality Indicators Project and the US National Healthcare Quality Report
Int. J. Qual. Health Care,
September 1, 2006;
18(suppl_1):
45 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hsu, M. Price, J. Huang, R. Brand, V. Fung, R. Hui, B. Fireman, J. P. Newhouse, and J. V. Selby
Unintended consequences of caps on medicare drug benefits.
N. Engl. J. Med.,
June 1, 2006;
354(22):
2349 - 2359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Morden and S. D. Sullivan
States' Control Of Prescription Drug Spending: A Heterogeneous Approach
Health Aff.,
July 1, 2005;
24(4):
1032 - 1038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Weiner, T E Stump, C M Callahan, J N Lewis, and C J McDonald
Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications
Qual. Saf. Health Care,
April 1, 2005;
14(2):
99 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Choudhry and A. S. Detsky
A Perspective on US Drug Reimportation
JAMA,
January 19, 2005;
293(3):
358 - 362.
[Full Text]
[PDF]
|
|
|
|
